glp-1 semaglutide weight loss treatments kentucky BREAKTHROUGH: FDA APPROVES TREATMENT FOR SERIOUS LIVER DISEASE Semaglutide, a medication already known for its role in management, is now the first GLP-1 therapy approved to treat MASH (Metabolic Dysfunction–Associated Semaglutide GLP-1 Weight Loss Injections

It also aligns with increasing emphasis on secondary prevention in patients with established cardiovascular disease

G.et al (2018)

Acknowledgements This study was supported by grants from the Tokyo Metropolitan Government and the Japan Agency for Medical Research and Development

These combined effects explain why tirzepatide produces substantial weight lossup to approximately 21% of body weight in adults without diabetes at the 15 mg dose in clinical trials, with somewhat lower averages in people with type 2 diabetesalongside improvements in hemoglobin A1c levels

This differs from muscle-building (where lean mass increases) and represents preservation of existing muscle during fat loss